Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 75 of 3284 entries
View as:

A Study of Lanabecestat (LY3314814) in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT02663128 Org: User:
Start: 01/31/16 End: 03/31/16 Due: 03/31/17

Open Label, Dose Escalation Phase I Study of AZD2281

Phase: N/A Priority: Normal
NCT ID: NCT00572364 Org: User:
Start: 11/30/07 End: 06/30/09 Due: 06/30/10

A Randomized, Open Label Study to Compare the Current Phase II and Planned Phase III Capsule Formulation of AZD6244

Phase: N/A Priority: Normal
NCT ID: NCT01635023 Org: User:
Start: 07/31/12 End: 10/31/12 Due: 10/31/13

Diagnosis and Response to Treatment Using a Reliable Gastroesophageal Reflux Disease (GERD) Questionnaire: An In Clinical Practice Study

Phase: N/A Priority: Normal
NCT ID: NCT00963144 Org: User:
Start: 07/31/09 End: 11/30/09 Due: 11/30/10

Change in Patient-Reported Outcomes in Severe Eosinophilic Asthma Patients Treated With Benralizumab Under Real-life Conditions

Phase: N/A Priority: Normal
NCT ID: NCT04184284 Org: User:
Start: 11/15/19 End: 12/19/23 Due: 12/19/24

Study of Artery Conditions of 'At-risk' Asian People Not on Lipid-lowering Drugs

Phase: N/A Priority: Normal
NCT ID: NCT00970918 Org: User:
Start: 10/31/09 End: 08/31/10 Due: 08/31/11

A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS

Phase: N/A Priority: Normal
NCT ID: NCT06008093 Org: User:
Start: 04/05/24 End: 03/20/31 Due: 03/20/32

AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients

Phase: N/A Priority: Normal
NCT ID: NCT00890825 Org: User:
Start: 04/20/09 End: 11/02/16 Due: 11/02/17

A Phase 2b Diabetic Kidney Disease Study

Phase: N/A Priority: Normal
NCT ID: NCT04170543 Org: User:
Start: 11/18/19 End: 05/16/23 Due: 05/16/24

A Trial to Learn How Safe AZD9550 is in People With or Without Type 2 Diabetes Who Are Overweight or Obese

Phase: N/A Priority: Normal
NCT ID: NCT06151964 Org: User:
Start: 09/29/23 End: 10/01/26 Due: 10/01/27

A Study to Assess the PK, PD, Safety and Tolerability of Eplontersen in Healthy Chinese Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT06527755 Org: User:
Start: 08/06/24 End: 11/15/24 Due: 11/15/25

To Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses AZD8848 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01818869 Org: User:
Start: 01/31/14 End: 02/28/14 Due: 02/28/15

Non-interventional Study of Patients With PN NF1 Starting Selumetinib in Russia

Phase: N/A Priority: Normal
NCT ID: NCT05891847 Org: User:
Start: 03/21/23 End: 03/20/26 Due: 03/20/27

Seroquel in Acute Mania: Study to Investigate if Valproate Add-On Therapy is Superior to Quetiapine Monotherapy in Acutely Manic Patients

Phase: N/A Priority: Normal
NCT ID: NCT00139074 Org: User:
Start: 07/31/05 End: 06/30/06 Due: 06/30/07

A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE

Phase: N/A Priority: Normal
NCT ID: NCT06897930 Org: User:
Start: 04/21/25 End: 05/01/29 Due: 05/01/30

A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)

Phase: N/A Priority: Normal
NCT ID: NCT06606847 Org: User:
Start: 09/24/24 End: 06/30/27 Due: 06/30/28

PRostate Olaparib Real World Evidence Study

Phase: N/A Priority: Normal
NCT ID: NCT06031805 Org: User:
Start: 10/11/23 End: 10/13/28 Due: 10/13/29

A Treatment With Fulvestrant and Exemestane in Postmenopausal Patients With Advanced Hormone Receptor-Positive (HR) + Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01171417 Org: User:
Start: 08/31/10 End: 11/30/13 Due: 11/30/14

Phase I Double-blind, Placebo-controlled Study of AZD7442

Phase: N/A Priority: Normal
NCT ID: NCT04896541 Org: User:
Start: 03/16/21 End: 06/14/22 Due: 06/14/23

Safety and Tolerability of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients Treated With Metformin and Sulfonylurea

Phase: N/A Priority: Normal
NCT ID: NCT00995787 Org: User:
Start: 10/31/09 End: 02/28/10 Due: 02/28/11

Study to Assess Safety, Tolerability and Pharmacokinetics After Single Doses of AZD1446 to Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT00803855 Org: User:
Start: 12/31/08 End: 04/30/09 Due: 04/30/10

A Study to Examine Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients With Type 2 Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT00612794 Org: User:
Start: 09/30/07 End: 05/31/08 Due: 05/31/09

Drug Interaction Study Between AZD3480 and Aripiprazole in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT00689559 Org: User:
Start: 03/31/08 End: 04/30/09 Due: 04/30/10

Clinical Use of EVUSHELD as Pre-exposure Prophylaxis in Real-world Setting in Gulf Cooperation Council Countries

Phase: N/A Priority: Normal
NCT ID: NCT05315323 Org: User:
Start: 06/23/22 End: 06/27/24 Due: 06/27/25

Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations

Phase: N/A Priority: Normal
NCT ID: NCT05687266 Org: User:
Start: 12/29/22 End: 11/01/27 Due: 11/01/28